GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » Investments And Advances

Bionomics (Bionomics) Investments And Advances : $0.08 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bionomics Investments And Advances?

Bionomics's Investments And Advances for the quarter that ended in Dec. 2023 was $0.08 Mil.

Bionomics's quarterly Investments And Advances stayed the same from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.08 Mil).


Bionomics Investments And Advances Historical Data

The historical data trend for Bionomics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics Investments And Advances Chart

Bionomics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bionomics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.08 - - 0.08

Bionomics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Bionomics (Bionomics) Business Description

Traded in Other Exchanges
Address
200 Greenhill Road, Eastwood, SA, AUS, 5063
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.